NextCure Reports Q2 Loss As Proposed Avere Merger Reshapes Strategic Direction

NextCure, Inc. (NXTC) reported a Q2 net loss of $14.9 million, compared with $26.8 million last year, while R&D expenses declined to $7.4 million. The company is advancing its proposed Avere Therapeutics merger, alongside a planned $320 million private financing.